Valeant Pharmaceuticals Intl Inc. vs. Baytex Energy Corp.: Which Is a Better Bet?

Contrarian investors are always searching for beaten-up stocks that could be on the cusp of a big rebound.

Let’s take a look at Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and Baytex Energy Corp. (TSX:BTE)(NYSE:BTE) to see if one deserves to be in your portfolio today.


It’s hard to believe that Valeant was Canada’s most valuable company by market cap for a brief moment last year.

Yup, Valeant traded for more than $330 per share at the end of July 2015 and was worth more than Royal Bank of Canada.

Today, Royal Bank is at an all-time high and is worth $136 billion. Valeant, on the other hand, is trading at $18.50 per share and is worth less than $6.5 billion.


Many investors have been badly burned trying to catch this falling knife, and there isn’t much reason to believe the stock has bottomed.

The company is trying to turn things around, but ongoing legal issues persist, and Valeant has said 2017 is going to be a tough year as it battles through patent expirations and weak sales in its dermatology business.

The stock originally jumped on the result of the U.S. election; investors are hoping that a Trump administration will be less problematic for drug companies, but Trump recently said he thinks drug prices are too high, so more political pain might be on the way for the sector.

What’s the upside?

Fans of the stock say the sell-off is overdone and that the underlying business is still attractive, especially if Valeant can find buyers willing to pay reasonable prices for some of its non-core assets.

This would help bring down the debt load, which sat at a massive US$30.4 billion at the end of Q3 2016.


Baytex is another fallen star in the Canadian market. The stock traded for $48 per share before the oil crash. In January, it hit $2 and has traded for less than $8 for most of the year.

Management has done a good job of keeping the company alive through the downturn. The company raised capital when the market had a brief uptick in 2015, and terms have been renegotiated with lenders to give the company more breathing room as it adjusts to lower oil prices.

Net debt was still $1.84 billion at the end of the third quarter, so more work has to be done, but the company is at least living within its cash flow while it waits for oil prices to rise.

The recent OPEC deal to reduce production is providing the sector with some optimism that a global supply glut could evaporate by the end of next year. If global producers actually honour their pact and oil supplies fall meaningfully, prices could drift higher in the coming months.

If that happens, Baytex has some strong upside potential, even after the big rally investors have enjoyed in the wake of the OPEC announcement.

Is one a better bet?

Both stocks are too risky for my taste, but contrarian investors who have a strong stomach for volatility might want to consider a bit of Baytex right now. The oil market appears to have bottomed out, and money is starting to flow back into the sector.

As for Valeant, I think there are too many unknowns today to risk buying the stock. It could very well double next year, but it could also hit $10 before bottoming out.

Stock Buy Alert Hits Astounding 96% Success Rate!

The hand-picked investing team inside Stock Advisor Canada, recently issued a buy alert for one special type of “bread-and-butter” stock where The Motley Fool U.S. has banked profits on 23 out of 24 recommendations. Frankly, with an astounding 96% success rate that has delivered average returns of 260%, chances are this new pick could deliver life-changing returns as well. Because the team at Stock Advisor Canada fully embraces the same time-tested investing philosophies that have led to countless Motley Fool winners globally. So simply click here to unlock the full details behind this new recommendation and join Stock Advisor Canada.

*96% accuracy includes restaurant stock recommendations from Motley Fool U.S. services Stock Advisor, Rule Breakers, Hidden Gems, Income Investor and Inside Value since each services inception. Returns as of 5/27/16.

Fool contributor Andrew Walker has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. I understand I can unsubscribe from these updates at any time. Please read the Privacy Statement and Terms of Service for more information.